Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discusses the Alvotech/AbbVie settlement for an adalimumab biosimilar and whether it will impact future patent lawsuits.
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discusses the Alvotech/AbbVie settlement for an adalimumab biosimilar referencing Humira and whether it will impact future patent lawsuits at the Academy of Managed Care Pharmacy (AMCP) annual meeting.
Transcript:
What do you think that the recent settlement between Alvotech and AbbVie could have for future patent lawsuits, especially for those that may involve the ITC [International Trade Commission]?
Casberg: First, what is the settlement agreement? So, [several] weeks ago, we had a settlement agreement between Alvotech and and AbbVie. Alvotech has a [adalimumab] biosimilar product they're looking to bring to market. AbbVie's the [reference] manufacturer and they'd prefer not to have more competition. But what happened is that both sides had their arguments, but both sides weren't completely sure they would win. And if they did have to go to litigation, the litigation could go on forever, and it could get very expensive.
So, for various reasons, both sides come to a meeting and they say, "Okay, we want this," and they negotiate. They come to a settlement agreement to say, "Okay, we agree that you can launch the biosimilar product, or generic in some cases, on this date." So, that occurred. And the agreement said that alphatech can launch AVT02, the new formulation [referencing] Humira in July 2023.
That changed everything as well, because there was a couple other companies out there, Celltrion Healthcare and Samsung Bioepis/Organon have products. And we hadn't heard much about them. And because we hadn't heard a lot about them, we had figured they probably also had settlement agreements, but weren't saying. So, the information was not publicly available. Now, IPD [Analytics] is assuming that if Alvotech has a settlement agreement with this date, it's likely that Celltrion and Samsung Bioepis/Organon have similar dates.
The settlement agreement is significant because payers can now negotiate with biosimilar manufacturers for both access to original formulation and new formulation products and not have to worry about the conversion effort that would have taken place if only the original formulation came out. So, it changed the game. It's going to make it a lot smoother for payers and a lot better for consumers of the product. It likely will increase adoption of these biosimilar. I think previous to a few weeks ago, adoption would have been modest year 1 [after launch]. I think it will be significantly more than modest now, especially in the second half of the year.
In 2023, we're going to get also interchangeable products. So, for the original formulation we're going to get Cyltezo by Boehringer Ingelheim and Abrilada by Pfizer both launching around July 1 with interchangeability. And then also around July 1, we'll may get the Alvotech/Teva Pharmaceuticals product AVT02 launching with interchangeability. How important is that interchangeability? I guess that's a whole nother session to talk about. So, we'll take that as it comes as [we see] additional launches in 2024 and later.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.